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receptor agonist, is effective at acutely enhancing mucociliary
clearance in healthy, nonsmoking adults. UTP solution for inhala-
tion is being developed by Inspire Pharmaceuticals under the com-
pound number INS316. In a double-blind, randomized, crossover,
placebo-controlled study we tested the single-dose effect of UTP




 15) by mea-

















aerodynamic diameter [MMAD]) after inhalation of nebulized pla-
cebo (0.9% saline) and two doses of UTP (20 and 100 mg in the
nebulizer). On each study day, gamma camera scanning was per-
formed over a 2-h period. After an initial deposition scan, subjects
inhaled placebo or UTP during the first 20 min of scanning. Analy-
sis of whole lung clearance showed that the retention-time curves
for each day were biphasic and that the earliest break point in the
average curves occurred at 50 min. Mean particle clearance rate








 0.27 whereas treatment with UTP showed Clr significantly








 0.44 for the 20-mg and 100-




 0.005 for both as compared with pla-
cebo. These data show that mucociliary clearance associated with
mild chronic bronchitis is acutely improved with minimal doses of
aerosolized UTP, presumably because of its stimulation of ciliary
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been shown to result in increased hydration of the airway sur-
face (2). Studies of normal airway epithelia have also shown
that triphosphate nucleotides are capable of stimulating ciliary
beat frequency (CBF) (3) and goblet cell degranulation (4).
These integrated effects of UTP on the airway epithelium may
thereby facilitate impaired mucociliary clearance.
Impaired mucociliary clearance may contribute to the patho-
physiology of several airway diseases such as chronic bronchi-
tis, cystic fibrosis, and asthma. We recently showed that UTP
dramatically stimulated mucociliary clearance (MCC) in nor-
mal subjects (5) and that UTP enhances cough clearance in
patients with primary ciliary dyskinesia (PCD) (6). Because
patients with PCD have dysfunctional cilia, they must rely on
cough to clear secretions from the surface of their airways. How-
ever, UTP may not be suitable as a therapeutic agent in the
treatment of chronic bronchitis and other obstructive pulmo-
nary diseases because the compound is rapidly degraded enzy-
matically within sputum and by airway epithelial cells (7). In-





 agonists for these indications. Because of
its rapid onset and expected short duration of action, UTP is
being developed (under the compound number INS316) as an
agent for obtaining deep-lung sputum specimens suitable for
diagnostic purposes such as for the cytologic detection of lung
cancer. In the present study, we measured the acute effect of
aerosolized UTP on the MCC of radiolabeled particles in
smokers with mild chronic bronchitis, a population likely to be






Fifteen (8 female/7 male) subjects with mild chronic bronchitis (mean
age 43 yr, range 32 to 54) were studied. All patients had a clinical diag-
nosis of chronic bronchitis based on the American Thoracic Society
(ATS) definition, i.e., excess mucus production, occurring on most
days for at least 3 mo of the year for at least two successive years. All













 80% and maximal midexpi-




 23. Subjects had
no acute respiratory exacerbation for 4 wk before testing. None of the
subjects was taking inhaled or oral bronchodilators during the period
of their study. The study was approved by the University of North
Carolina Committee on the Protection of the Rights of Human Sub-




Subjects were studied on a control (i.e., no treatment) day and on
three treatment days in a crossover design. The three treatment days
(0.9% saline, 20 mg UTP, and 100 mg UTP) were randomized, dou-
ble-blinded, and separated by no more than 1 wk. The 20-mg dose was
similar to that used in previous studies of normal and PCD subjects
without any adverse effects (5, 6). The 100-mg dose was found to be
safe and well tolerated in a dose-escalating study of aerosolized UTP
in a similar group of chronic bronchitics as those studied here (8).
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6). To match airway deposition of the aerosol on the four study days, tidal
flow (500 ml/s) and breathing frequency (30/min) were controlled by hav-
ing the patient monitor tidal flow on an oscilloscope. Subjects inhaled the





Ci) in the lung for clearance measurements. With the
subject seated in front of the gamma camera (Elscint Apex 415 gamma
camera interfaced with an Elscint Model 109 computer; Elscint, Haifa, Is-
rael), an initial deposition scan (the sum of two 2-min scans) was re-
corded and then continuous 2-min images were recorded for a period
of 2 h. Subjects also returned at 24 h postdeposition for a 30-min scan.
After the initial deposition scan on the treatment study days, the
patient received the randomized, aerosol treatment delivered by PARI
LC Plus Jet nebulizer (PARI, Midlothian, VA) (4 ml of 0.9% saline,
5-mg/ml UTP, or 20-mg/ml UTP) during tidal breathing over a 15-min
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the aerosolized treatments. The frequency and times of these coughs
were recorded for comparison between the four study days. To assess
the safety of each single-dose UTP treatment (and placebo), we mon-
itored oxyhemoglobin saturation and blood pressure throughout the
dosing period and until the end of the gamma camera monitoring, and
measured forced expiratory volumes and flows by spirometry before
and immediately after MCC measures.
The nebulizer was powered by a DeVilbiss Pulmoaide compressor
(De Vilbiss, Somerset, PA). Particle size of the UTP solution droplets
was determined by complete drying of particles after nebulization fol-
lowed by cascade impaction of the dried particles. The original drop-
let size distribution was then calculated from the “dry” size distribu-
tion and the original mass concentration of the solution (9). For these













 0.05 for two-tailed analysis. Unless other-




 standard deviation of
the means.
On the initial study day, a xenon-133 equilibrium lung scan was re-
corded for each subject (5, 6) to create regions of interest for deter-
mining regional distribution and retention of the deposited aerosol.
Only the right lung was used for analysis because of interference from
stomach activity on the left side. To assess the degree of central (C)




Tc activity (5, 6) for the initial 2-min deposition scan, normalized to
the xenon equilibrium scan. The C/P ratio was used to determine if
initial particle deposition for the four study days was similar.
A rectangular region bordering the whole right lung (defined by
the Xe-133 equilibrium scan) was used to determine by computer
analysis the lung retention (R), expressed as a percentage of the initial
decay-corrected counts, in the right lung over the 2-h period and at
24 h. Analysis of regional clearance was performed by constructing a
smaller rectangular region (approximately 25% by area of the whole
right lung region) to define the central region (5, 6). Clearance from
both the central and the outer peripheral region (lying between the
central and the whole lung rectangle) was also determined. Although
both regions overlap bronchial airways as well as parenchyma, the
central region contains the largest proximal airways (mainstem and
lobar bronchi) not contained in the peripheral zone.
Figure 1. (A) Initial deposition
gamma camera images on con-
trol (left) and UTP (right) study
days of one subject. Region of
interest around right lung was cre-
ated from xenon-133 equilibrium
scan. (B) Gamma camera images
at 30 min after deposition of ra-
diolabeled particles for control
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By fitting a polynomial to the whole lung retention (R) versus time
data from all study days and patients, a change point, defined as the
earliest time point for which the quadratic term of time became statis-
tically significant, was estimated (5). The common change point for all
treatment study days was estimated to be 50 min (Figure 2), whereas
for the control day there was no statistically significant change point
in the clearance curve. In each patient a clearance rate (Clr in %/min)
was then determined for each study day as the slope of a linear regres-









 0 to 50 min. Similar rates for central and peripheral clearance
were determined for each study day in each patient. The same period




 0 to 50 min) was used for whole, central,
and peripheral lung clearance rates so that direct comparisons be-
tween regions could also be made. Initial comparisons between differ-
ent drug treatments were made by repeated measures analysis (Systat
for Macintosh; SPSS, Evanston, IL) of Clr, C/P, and 24-h retention for
each study day. Comparison of cough frequency on the four study
days was made by Friedman nonparametric rank analysis for repeated
measures. Multivariate analysis (Systat for Macintosh) was also per-
formed to determine the role of other covariates to any observed dif-
ferences in Clr for the different treatment study days. Variables
considered were treatment, initial deposition pattern (C/P ratio),
cough frequency over the period of interest, and interactions between




Gamma camera images from a representative subject are illus-
trated in Figure 1. Figure 1A shows initial deposition scans
(time 0) on a control (i.e., no treatment) versus a UTP study
day. Figure 1B, at 30 min postdeposition (or approximately 15
min after completion of aerosolized UTP treatment for that
day) shows that on the control study day little activity appears
to have moved from the region of interest surrounding the right
lung into the trachea. On the other hand, by 15 min after treat-
ment with UTP, a considerable amount of radiotracer has al-
ready left the lung in transit up the trachea. Figure 2 illustrates




Tc–iron oxide for the four
study days (control, placebo, and two doses of UTP) in all sub-
jects. Table 1 gives the mean Clr in %/min, C/P ratios, 24-h re-
tentions, and number of coughs through 50 min for each study
day. By repeated analysis, there were significant differences in









parisons showed that both doses of UTP produced, on aver-
age, a 100% increase in whole lung clearance rate (Clr) com-





 0.005). Whole lung Clr was, on average, 38% greater for




 0.01). There was no difference in
Clr between the two doses of UTP. There was no significant
difference in either C/P ratios or 24-h retentions between the
four study days, but cough frequency was significantly differ-




 0.001 by Friedman non-
parametric rank analysis for repeated measures). Frequency
of spontaneous coughing was greater than control for both




 0.001) and was UTP dose related, i.e., sig-
nificantly more coughing with the higher dose of aerosolized




 0.005). Despite a tendency for greater
cough with the low-dose UTP (20-mg) compared with pla-




 0.07). There was
also no difference in cough frequency between placebo and
control test days.
Linear regression analysis of the retention versus time data
for the period 50 to 120 min in Figure 1 (i.e., after the change





cept was shifted with both saline and UTP treatment. This
shift suggests an increasing portion of the deposited particles
being cleared during the fast phase of the clearance curve (i.e.,
0–50 min) with all treatments. The percentage of deposited
particles being cleared as part of the fast phase of clearance
(as estimated from the zero intercept retention versus time
over the range 50 to 120 min) increased from 12% for control
to 25% for saline to 38% for both UTP treatments. Thus, not
only did the rate of fast-phase clearance (Clr) increase with
UTP treatment (by approximaely 50% compared with pla-
cebo) but the size of the compartment (number of airways)
participating in the fast phase of MCC was also increased (also
by approximately 50%).
Figure 3 illustrates mean central lung clearance for the four
study days. Clr from the central lung region were faster than
the respective whole lung rates for both doses of UTP but not




 0.001). As with whole
lung clearance, there were significant differences in central




 0.001). Both doses of
UTP enhanced central lung clearance relative to placebo (p 
 

Figure 2. Mean whole lung clearance (retention versus time) for con-
trol (	), placebo (), 20 mg UTP (), and 100 mg UTP (
).
 
TABLE 1. SUMMARY OF RESULTS
 











































































































Figure 3. Mean central lung clearance (retention versus time) for con-
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0.001). Similarly, central lung Clr was significantly greater for





Figure 4 illustrates mean peripheral lung clearance for the
four study days. Clr from the peripheral lung region were
slower than the respective whole lung rates for both doses of





with whole and central lung clearance, there were significant




0.001). Both doses of UTP enhanced peripheral lung clear-




 0.05). Unlike whole lung and
central Clr, however, Clr for the peripheral region was not sig-




 0.06) for placebo versus control.
Multivariate analysis of Clr for the whole lung showed that
subject, treatment, and the interaction between treatment and




0.01 in each case). Thus, the differences in Clr within a subject
could be primarily explained by treatment with placebo and
the two doses of UTP. Also, the variation in Clr as a function
of C/P (i.e., slope of Clr versus C/P) was different for the dif-
ferent treatment arms (i.e., the significant interaction between
treatment and C/P ratio). This translated into a greater effect
of the UTP treatments on Clr for those subjects with higher C/P
ratios or more central airway deposition. This is consistent
with the larger effect of UTP seen on central versus peripheral
airway clearance (Figure 2 versus Figure 3 and Table 1). In the





 0.3) associated with C/P alone nor the number of coughs
in 50 min, either alone or the interaction between treatment
and number of coughs. In other words, despite the significant
difference in cough number between the different treatment
days (Table 1), it was not predictive of the difference in Clr
observed.
The safety measures during the study showed no significant
effects of either single-dose UTP treatment on blood pressure.
Oxyhemoglobin saturation was transiently decreased below
90% (range 83 to 89%) in some subjects during UTP inhala-
tion and up to 5 min after completion of dosing. This decrease
in oxyhemoglobin saturation seemed to be dose-dependent,
occurring in three of 15 subjects for the 20-mg dose of UTP
and in nine of 15 subjects for the 100-mg dose of UTP. No
such fall in oxyhemoglobin saturation occurred on the placebo
study days. By the end of MCC measures, i.e., 2 hr after dos-
ing, oxyhemoglobin saturation was equal to or greater than pre-
dosing values for all treatments. Spirometry measures showed




 between pre-MCC and post-MCC
measures on the UTP or placebo dosing days. There was a








Similar to our previous findings in nonsmoking, healthy sub-
jects (5) we have found in the present study that UTP acutely
stimulates MCC in mild chronic bronchitics. The relative in-
crease in Clr for the whole lung after UTP administration
was similar to that seen previously in the healthy, nonsmoking
subjects (5). The 20-mg dose of UTP (5 mg/ml) used in this






 M solution of UTP used in the
previous study (5). Both studies showed an approximate dou-
bling of the rate of clearance during and immediately after
UTP inhalation. This similarity to nonsmokers also suggests that
degradation of the UTP in airway secretions or epithelial cells
in these chronic bronchitics did not occur to a greater extent
than likely occurred in the healthy nonsmokers. In the present
study, increasing the dose of UTP 5-fold (i.e., to 100-mg)
caused no further enhancement of the clearance rate during
the period of observation. Thus, it may be that the lower dose
of UTP (20-mg) maximally enhances MCC over the 50-min
period of observation through its effects on ciliary beat fre-
quency (3) and improved hydration of the airway surface (2).
A single dose of UTP administration to patients with mild
chronic bronchitis also produces an acute increase in sputum
expectoration (8). This increase may be attributed to im-
proved hydration of secretions (2) or enhanced mucin secre-
tion (4). The mild decreases in oxyhemoglobin saturation and
MMEF for the high dose of UTP that we observed may also
be a reflection of enhanced secretions in the lung periphery.
Though UTP has been demonstrated to stimulate mucin se-
cretion (4), increased mucin secretion alone apparently adds
little to the rate of MCC in smokers already exhibiting more
mucus on their airways than normal (10, 11). Increased mucus
secretion in healthy airways with a less continuous mucus
blanket, on the other hand, may contribute to the enhanced
MCC observed in the normal lung (5).
It is difficult to discern from this study the length of time
that a single aerosolized UTP treatment may be effective for
enhancing MCC. On the one hand, the time course of sputum
production shows the peak production occurring immediately
to 30 min after UTP inhalation (8). This seems to correspond
to the acute speeding of clearance we find in the first 30 min
after treatment. However, the change in clearance rate at or
about 50 min on the UTP treatment days is also likely to be a
reflection of near complete clearance of labeled particles from
the bronchial airways. The UTP may continue to be active be-
yond this time period, but the loss of tracer from ciliated air-
ways makes such action undetectable. For this reason it may
be that the higher dose of UTP has a longer period of action
but, again, is undetectable. Sabater and coworkers (12) re-













 M) on tracheal mucus velocity
(TMV) over a 4-h period in sheep. In these studies the greatest
increase in TMV was seen 15 to 30 min after aerosolized UTP
treatment. The enhanced TMV over control was still present,
however, at 2 h posttreatment for both doses of UTP, and at 4
h posttreatment for the higher dose (comparable to 50 mg/ml).
The enhanced clearance rates after UTP treatment were
more dramatic in the central lung regions, suggesting that un-
der the aerosol delivery conditions used here, i.e., tidal breath-
ing from a Pari LC Plus nebulizer, the larger bronchial airways
may be most affected. The finding that the UTP effect on
whole lung clearance was most dramatic in those subjects with
the higher C/P ratio also suggests a greater effect to the larger
airways. These regional effects may be dependent on the con-
ditions of both the radiolabeled and UTP aerosol inhalations
and particle sizes. The particle size and breathing conditions
Figure 4. Mean peripheral lung clearance (retention versus time) for












Tc–iron oxide particles were chosen to enhance air-
way deposition. Our 24 h retention values (Table 1) suggest
that as much as 60% of the particles were deposited on cili-
ated airway surfaces. The particle size for the UTP aerosol









m), suggesting that both may have distributed
similarly along the bronchial tree in each subject. Had we cho-
sen particle sizes and breathing conditions to maximize parti-
cle deposition of both the labeled marker and the nebulized
UTP in small airways of the lung (13), we may have seen a
more dramatic effect of UTP on the peripheral lung region. It
should also be emphasized that the peripheral regions, as de-
fined by our gamma camera analysis, had a greater percentage
of alveolar to total deposition than central regions (the mean
24-h retention for peripheral regions versus central regions on




 0.43 versus 0.35, respectively). Because alveo-
lar clearance of particles occurs very slowly (weeks to months)
and is unlikely to be affected by UTP treatment, this differ-
ence in deposition distribution would tend to reduce the effect
of treatment on peripheral clearance rates over all periods of
observation.
The frequency of spontaneous coughing was increased in
response to aerosolized UTP treatment here and in the dose
escalation safety studies (8). However, despite the increased
coughing, Clr was not dependent on cough frequency in the
multivariate analysis. Similarly, despite the much greater cough
frequency seen with the higher dose of UTP, the Clr from any
lung region was not different from that of the lower dose. The
increased cough frequency with the higher concentration of
UTP may be another reflection of increased mucus produc-
tion at this dose. Cough can be effective at enhancing secre-
tions in chronic bronchitics with more severe disease and
likely more hypersecretion than those studied here (14). How-
ever, in a previous study we showed that voluntary, controlled
cough (60 controlled coughs over the first 60 min of MCC
measurements) was not effective at enhancing MCC in smok-
ers with normal lung function such as those of our present
study (15). Thus, it is unlikely that increased cough is solely re-
sponsible for the enhancement of clearance by UTP, but it
may have aided clearance once UTP had enhanced or mobi-
lized secretions in the airways. As an example of how cough
may work in concert with UTP effects on secretions, we
showed recently that when ciliary function is lost, i.e., in PCD,
UTP aids in the clearance of secretions by cough (6). In this
case cough is the primary, if not only, means by which secre-
tions are cleared from the airways but UTP likely enhanced
mobilization or clearability of the secretions for cough clear-
ance to be enhanced in these patients with PCD.
The limited safety assessments of this study suggest that the
UTP treatments, especially at the low 20-mg dose, are well tol-
erated. More extensive safety assessment at even higher doses
in similar patients has shown no serious adverse events (8).
There appears to be a dose effect on cough frequency, oxyhe-
moglobin desaturation, and MMEF that is likely a reflection
of increasing secretions at the higher 100-mg dose of UTP.
Dose escalation studies (8) have also shown greater sputum
production with escalating doses of UTP. Yet we have shown
here that the low dose of UTP (20 mg) produces substantial
enhancement of MCC rates with minimal side effects.
Smokers with mild chronic bronchitis, such as those studied
in the present study, have been shown previously to have
mildly depressed mucociliary clearance compared with nor-
mal (16, 17). We have shown in the current study and other
studies that a relatively low dose of aerosolized UTP is well
tolerated, enhances the rate of MCC, and enhances sputum





 agonists have therapeutic potential for treating the im-
pairment of mucociliary clearance associated with obstructive
lung diseases, such as chronic bronchitis, cystic fibrosis, and
PCD. Because UTP is susceptible to enzymatic degradation




 agonists being devel-
oped may be more appropriate for treating chronic obstruc-
tive lung diseases. However, the ability of UTP to rapidly
stimulate MCC and to thereby enhance the quality of expecto-
rated sputum (8) may make this compound ideally suited as a
single-use, sputum induction agent for acquiring diagnostic
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